GlassScriptPhysician profile
Mary J Walker
NPI 1023051067
$3,271.92
in general payments reported to CMS, 2019-2025
25 companies · $557 in 2025
The $557 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $539 · 2022: $491 · 2023: $980 · 2024: $705 · 2025: $557.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,242.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,242.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $425.30 | 2023-2024 | Puraply Wound Matrix, Puraply Antimicrobial, Affinity |
| Avanir Pharmaceuticals, INC. | $368.19 | 2021-2022 | |
| Acadia Pharmaceuticals INC | $344.60 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $296.74 | 2021-2024 | |
| Eisai INC. | $227.39 | 2023-2025 | |
| Novo Nordisk INC | $226.59 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Otsuka America Pharmaceutical, INC. | $218.92 | 2023-2025 | Rexulti, Nuedexta |
| Lilly USA, LLC | $215.06 | 2022-2025 | Kisunla, Zepbound, Amyvid |
| Glaxosmithkline, LLC. | $174.51 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $138.87 | 2023 | Evenity, Prolia |
| Xeris Pharmaceuticals, INC. | $99.43 | 2021-2023 | Gvoke Hypopen |
| Bayer Healthcare Pharmaceuticals INC. | $97.25 | 2023-2025 | |
| Lundbeck LLC | $56.96 | 2024-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.51 | 2021-2022 | |
| Pfizer INC. | $42.68 | 2021-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $42.15 | 2023-2024 | Veozah |
| Neurocrine Biosciences, INC. | $40.97 | 2024-2025 | Ingrezza |
| Abbvie INC. | $39.80 | 2023-2024 | |
| Sumitomo Pharma America, INC. | $36.20 | 2025 | Gemtesa |
| Astrazeneca Pharmaceuticals LP | $31.34 | 2023 | Farxiga |
| Boston Scientific Corporation | $25.08 | 2023 | |
| Axsome Therapeutics, INC. | $19.81 | 2025 | Auvelity |
| Alkermes, INC. | $18.51 | 2022 | |
| Corium, LLC | $17.94 | 2023 | Adlarity |
| Vanda Pharmaceuticals INC. | $15.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.